Board of Directors

OFFICERS
Christopher Fausel, PharmD, MHA, BCOP — Chairman
Bert O’Neil, MD — Chief Medical Officer
Charles Fox — Secretary/Treasurer

MEMBERS-AT-LARGE
Sumeet Bhatia, MD
Kerry Bridges, MBA, RN, CCRC
Christopher LeMasters, MBA
Ziyue Liu, PhD (non-voting)
Patrick Loehrer, Sr., MD
Annette Moore, MD
Timothy Ratliff, PhD
Richard Zellars, MD
The year 2014 brought rapid fire change and accomplishment for the Hoosier Cancer Research Network (HCRN). It’s all in a name … the Hoosier Oncology Group Board of Directors voted to change the name of the organization to the Hoosier Cancer Research Network in the spring of 2014. The decision was based on the increasing reach and scope of clinical trials conducted by HCRN. While HCRN is based in Indiana and is fiercely proud of its Hoosier roots, the organization has evolved over 30 years to become a nationally recognized not-for-profit cancer research organization with more than 150 clinical trial sites, including some outside the United States. The new name maintains the well-established ties to our Hoosier lineage while accurately describing what it is that we do: we facilitate the development of clinical trials through a Cancer Research Network.

A second major change in 2014 for HCRN was a change of address. With the office space on West 10th Street potentially being sold, the decision was made for HCRN to be proactive about finding a new residence. Fortunately, we were able to sign a lease at the old Safeco building at 500 North Meridian Street in downtown Indianapolis. The new site provides a larger biorepository facility to reflect the growing importance of banking tumor samples in the era of genomically based cancer clinical trials, adequate meeting space, and an office layout that promotes staff engagement and creativity.

HCRN in 2014 began the huge task of migration to a new electronic data capture system. HCRN migrated all existing clinical trials to the OnCore system that is supported by Forte Research Systems in Madison, Wis. Established in 2000, OnCore has been implemented by numerous research organizations across the United States, including many major cancer centers, to manage clinical trial data. The Data Systems team, led by Tim Breen, PhD, MS, CCDM, met the challenge of building all of the existing trial database in the new OnCore system and provided outstanding feedback to the Forte Research Systems corporate office about innovative modifications to allow OnCore to better accommodate multicenter clinical trials.

As Dr. O’Neil points out in his letter on the next page, the scientific acumen in HCRN and Big Ten Cancer Research Consortium clinical trials continues to flourish. The era of personalized medicine is now upon us, and Hoosier Cancer Research Network is ideally positioned to offer high-quality clinical trials that answer crucial clinical questions for cancer patients in communities large and small in Indiana, at Big Ten cancer centers, and at sites across the United States and beyond. We look forward to a productive 2015, with the ultimate end goal of making cancer a thing of the past.

Christopher A. Fausel, PharmD, MHA, BCOP
Chairman, HCRN Board of Directors

“The era of personalized medicine is now upon us, and Hoosier Cancer Research Network is ideally positioned to offer high-quality clinical trials that answer crucial clinical questions for cancer patients in communities large and small in Indiana, at Big Ten cancer centers, and at sites across the United States and beyond.”
As I reflect on the past year, let me say how much I have enjoyed my new position as chief scientific officer of Hoosier Cancer Research Network. Getting to know the leadership and the staff has been a wonderful experience, and I have been very impressed with how HCRN operates. What an amazing group of people. I have come to HCRN in a time of tremendous change and opportunity. I would like to focus on a couple of highlights from the past year.

We spent quite a bit of time on our biggest (no pun intended) new venture, the **Big Ten Cancer Research Consortium (BTCRC)**. This exciting organization really took flight this year, with a number of groups (thoracic cancers, urologic cancers, gastrointestinal cancers, breast cancer) meeting and developing concepts. By the end of the year, two concepts reached mature stage (one from the GU group and one from the GI group) and in early 2015, the BTCRC activated its first trial.

The BTCRC named Susan Goodin from Rutgers the second executive officer of the BTCRC, taking over for Noah Hahn, to whom much is owed for the early success of this venture. We expect over the coming year to see several new concepts funded and hopefully activated as the groups have gotten to know each other better and are sharing many excellent concepts.

It was a busy year for the HCRN working groups as well. As a gastrointestinal oncologist, one of my goals was to reinvigorate the GI efforts in HCRN. We did just that, inviting several new academic members into the group (Ohio State, North Carolina, Emory, Moffitt Cancer Center, University of Virginia, and more), and have generated several concepts, some of which have been or will soon be activated. In similar fashion, the thoracic group was quite active, producing two new funded concepts. The genitourinary group was typically active and generated three new funded concepts with more in the pipeline. New members were added to each of the working groups during the year, and HCRN is launching new groups in melanoma, symptom management, myeloma, lymphoma, and leukemia.

I think all at HCRN would agree that 2014 was a busy and fulfilling year. I would like to thank all of our excellent and hardworking staff, our leadership team, and all of our dedicated investigators and their wonderful staff for continuing to support our mission to bring cancer research to the community nationwide.

Bert H. O’Neil, MD
LUN06-113: Oral Abstract Session
A randomized double blind phase II trial of platinum (P) plus etoposide (E) +/- concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive stage (ES) small cell lung cancer (SCLC): Hoosier Cancer Research Network LUN06-113

LUN07-130: General Poster Session
Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies: Hoosier Cancer Research Network LUN07-130

BRE09-146: Poster Highlights Session
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Hoosier Cancer Research Network BRE09-146 (Numerous abstracts published utilizing matched pretreatment biopsies from BRE09-146)

QL12-153: General Poster Session
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients with Germ Cell Tumors Undergoing 5-Day Cisplatin-Based Chemotherapy: Hoosier Cancer Research Network QL12-153

GU12-160: General Poster Session

GYN10-149: General Poster Session
Clinical phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in recurrent platinum-resistant ovarian cancer: Hoosier Cancer Research Network GYN10-149
Financial Statements

We have audited the accompanying financial statements of the Hoosier Cancer Research Network, Inc., (the “Organization”) which comprise the statements of financial position as of June 30, 2014 and 2013, and the related statements of activities and cash flows for the years then ended, and the related notes to the financial statements.

Management’s Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility
Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Hoosier Cancer Research Network, Inc. as of June 30, 2014 and 2013, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matter
Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The supplementary schedules of functional expenses are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Crowe Horwath LLP
Indianapolis, Indiana
October 29, 2014
## Financial Statements continued

**HOOSIER CANCER RESEARCH NETWORK, INC.**  
**STATEMENTS OF FINANCIAL POSITION**  
**June 30, 2014 and 2013**

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 3,604,943</td>
<td>$ 2,256,786</td>
</tr>
<tr>
<td>Accounts and grants receivable, net</td>
<td>1,572,380</td>
<td>1,979,428</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>72,895</td>
<td>153,157</td>
</tr>
<tr>
<td>Investments (Note 2)</td>
<td>1,005,395</td>
<td>996,723</td>
</tr>
<tr>
<td>Bequest receivable (Note 3)</td>
<td>431,173</td>
<td>1,910,878</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>25,000</td>
<td>-</td>
</tr>
<tr>
<td>Property and equipment, net (Note 4)</td>
<td>77,942</td>
<td>24,550</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$ 6,789,728</strong></td>
<td><strong>$ 7,321,522</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$ 357,968</td>
<td>$ 330,327</td>
</tr>
<tr>
<td>Affiliate sites payable (Note 1)</td>
<td>311,352</td>
<td>278,966</td>
</tr>
<tr>
<td>Accrued payroll and vacation</td>
<td>132,930</td>
<td>103,239</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>158,000</td>
<td>141,000</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>960,250</strong></td>
<td><strong>853,532</strong></td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>5,183,187</td>
<td>4,381,994</td>
</tr>
<tr>
<td>Temporarily restricted (Note 1)</td>
<td>646,291</td>
<td>2,085,996</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>5,829,478</strong></td>
<td><strong>6,467,990</strong></td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$ 6,789,728</strong></td>
<td><strong>$ 7,321,522</strong></td>
</tr>
</tbody>
</table>

*The complete independent auditor’s report, including notes to financial statements, is available upon request.*
## Financial Statements

HOOSIER CANCER RESEARCH NETWORK, INC.

STATEMENTS OF ACTIVITIES

Year ended June 30, 2014 (with summary total for the year ended June 30, 2013)

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporary</th>
<th>2014 Total</th>
<th>2013 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td></td>
<td>Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>External support – research</td>
<td>$ 3,526,295</td>
<td>$ -</td>
<td>$ 3,526,295</td>
<td>$ 4,855,093</td>
</tr>
<tr>
<td>Federal research grants</td>
<td>9,978</td>
<td>-</td>
<td>9,978</td>
<td>42,640</td>
</tr>
<tr>
<td>Contributions and other grant support</td>
<td>516,806</td>
<td>80,295</td>
<td>597,101</td>
<td>2,262,230</td>
</tr>
<tr>
<td>Interest income from cash</td>
<td>5,533</td>
<td>-</td>
<td>5,533</td>
<td>6,572</td>
</tr>
<tr>
<td>Net investment loss (Note 2)</td>
<td>8,672</td>
<td>-</td>
<td>8,672</td>
<td>(3,277)</td>
</tr>
<tr>
<td>Other income</td>
<td>12,713</td>
<td>-</td>
<td>12,713</td>
<td>5,150</td>
</tr>
<tr>
<td>Releases from restriction</td>
<td>1,520,000</td>
<td>(1,520,000)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total revenues</strong></td>
<td>5,599,997</td>
<td>(1,439,705)</td>
<td>4,160,292</td>
<td>7,168,408</td>
</tr>
</tbody>
</table>

| **Expenses**           |              |             |            |            |
| Program services       |              |             |            |            |
| Investigator initiated research | 3,341,904    | -           | 3,341,904  | 2,359,217  |
| Industry research      | 497,283      | -           | 497,283    | 1,368,770  |
| Government research    | 25,925       | -           | 25,925     | 73,928     |
| **Total program services** | 3,865,112    | -           | 3,865,112  | 3,801,915  |

| Supporting services    |              |             |            |            |
| Administration         | 933,692      | -           | 933,692    | 694,906    |
| **Total supporting services** | 933,692      | -           | 933,692    | 694,906    |
| **Total expenses**     | 4,798,804    | -           | 4,798,804  | 4,496,821  |

| **Change in net assets** |              |             |            |            |
| 801,193                | (1,439,705)  |             | (638,512)  | 2,671,587  |

| Net assets, beginning of year | 4,381,994 | 2,085,996 | 6,467,990 | 3,796,403 |

| **Net assets, end of year** | $ 5,183,187 | $ 646,291 | $ 5,829,478 | $ 6,467,990 |

The complete independent auditor’s report, including notes to financial statements, is available upon request.
## Financial Statements continued

### HOOSIER CANCER RESEARCH NETWORK, INC.  
**STATEMENTS OF CASH FLOWS**  
Years ended June 30, 2014 and 2013

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$(638,512)</td>
<td>$2,671,587</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash from operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>15,335</td>
<td>9,146</td>
</tr>
<tr>
<td>Unrealized gain (loss) on investments</td>
<td>(492)</td>
<td>4,187</td>
</tr>
<tr>
<td>Change in assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts and grants receivable</td>
<td>407,048</td>
<td>(106,573)</td>
</tr>
<tr>
<td>Bequest receivable</td>
<td>1,479,705</td>
<td>(1,910,878)</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>80,262</td>
<td>(6,185)</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>27,641</td>
<td>44,185</td>
</tr>
<tr>
<td>Affiliate sites payable</td>
<td>32,386</td>
<td>6,503</td>
</tr>
<tr>
<td>Accrued payroll and vacation</td>
<td>29,691</td>
<td>38,403</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>(25,000)</td>
<td>-</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>17,000</td>
<td>141,000</td>
</tr>
<tr>
<td><strong>Net cash from operating activities</strong></td>
<td>1,425,064</td>
<td>891,375</td>
</tr>
</tbody>
</table>

| **Cash flows from investing activities** |            |            |
| Purchase of property and equipment | (68,727)   | (8,261)    |
| Purchase of investments           | (8,180)    | (1,000,910) |
| **Net cash from investing activities** | (76,907)   | (1,009,171) |

Net change in cash and cash equivalents | 1,348,157 | (117,796) |

Cash and cash equivalents at beginning of year | 2,256,786 | 2,374,582 |

Cash and cash equivalents at end of year | $3,604,943 | $2,256,786 |

The complete independent auditor’s report, including notes to financial statements, is available upon request.
Member Network

Academic Sites

ALABAMA
University of Alabama at Birmingham Comprehensive Cancer Center

ARIZONA
Mayo Clinic Cancer Center, Phoenix

CALIFORNIA
City of Hope
University of California Los Angeles (TRIO)
USC Norris Comprehensive Cancer Center

COLORADO
University of Colorado Cancer Center

FLORIDA
University of Florida Health Cancer Center
University of Miami

GEORGIA
Winship Cancer Institute of Emory University

ILLINOIS
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Chicago Medical Center

INDIANA
Indiana University Melvin and Bren Simon Cancer Center

KENTUCKY
University of Louisville

LOUISIANA
LSU Health Care Center

MARYLAND
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
University of Maryland Greenebaum Cancer Center

MASSACHUSETTS
Dana-Farber Cancer Institute
Tufts Medical Center

MICHIGAN
University of Michigan Comprehensive Cancer Center

MINNESOTA
Mayo Clinic Rochester (TBCRC)

MISSOURI
Washington University School of Medicine / Siteman Cancer Center

NEW HAMPSHIRE
Dartmouth-Hitchcock Norris Cotton Cancer Center

NEW JERSEY
John Theurer Cancer Center at Hackensack University Medical Center
Memorial Sloan Kettering Cancer Center, Basking Ridge
Rutgers Cancer Institute of New Jersey

NEW MEXICO
University of New Mexico Cancer Center (NMCCA)

NEW YORK
Icahn School of Medicine at Mount Sinai
Memorial Sloan Kettering Cancer Center, Commack
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, Rockville Centre
Memorial Sloan Kettering Cancer Center, Sleepy Hollow
New York University Cancer Institute
Roswell Park Cancer Institute
University of Rochester Medical Center

NORTH CAROLINA
Comprehensive Cancer Center of Wake Forest University
Duke University Medical Center (TBCRC)
University of North Carolina Lineberger Comprehensive Cancer Center

OHIO
Cleveland Clinic Taussig Cancer Institute
The Ohio State University
University of Cincinnati Cancer Institute
University Hospitals Seidman Cancer Center

OREGON
Oregon Health & Sciences University

PENNSYLVANIA
Fox Chase Cancer Center
Thomas Jefferson University / Sidney Kimmel Cancer Center
University of Pennsylvania

SOUTH CAROLINA
Medical University of South Carolina / Hollings Cancer Center

TEXAS
Baylor College of Medicine - Methodist Breast Center
Cancer Therapy & Research Center at UT Health Science Center
MD Anderson Cancer Center
The Methodist Hospital, Houston
UT Medical Branch at Galveston

WASHINGTON
University of Washington

WASHINGTON, D.C.
Georgetown University Medical Center (TBCRC)

WISCONSIN
Froedtert & the Medical College of Wisconsin
University of Wisconsin Carbone Cancer Center

CANADA
Cancer Care Manitoba, Winnipeg
Centre Hospitalier de l’Université de Montréal, Montréal

PERU
Instituto de Enfermedades Neoplasticas, Lima

UNITED KINGDOM
Centre for Experimental Cancer Medicine, London

Research Networks

NMCCA: New Mexico Cancer Care Alliance
SCCA: Seattle Cancer Care Alliance
TBCRC: Translational Breast Cancer Research Consortium
TRIO: Translational Research in Oncology
ARIZONA
Yuma Regional Cancer Center, LLC, Yuma

ARKANSAS
Genesis Cancer Center, Hot Springs

CALIFORNIA
Central Coast Medical Oncology Corp. (TRIO), Santa Maria
Marin Specialty Care, Greenbrae
Prostate Oncology Specialists, Inc., Marina Del Rey
St. Jude Heritage Healthcare (TRIO), Fullerton
West Valley Hematology Oncology (TRIO), Northridge

FLORIDA
Memorial Breast Cancer Center at Memorial Regional Hospital, Hollywood

ILLINOIS
Illinois Cancer Care, PC, Galesburg

INDIANA
Community Healthcare - Primary Care Oncology, Munster
Community Regional Cancer Centers, Indianapolis
Floyd Memorial Cancer Center of Indiana, New Albany
Fort Wayne Medical Oncology & Hematology, Fort Wayne
Good Samaritan Hospital, Vincennes
Hope Center, Terre Haute
Horizon Oncology Research, Inc., Lafayette
IU Health Annett Cancer Centers, Lafayette
IU Health Ball Memorial Hospital Cancer Center, Muncie
IU Health Cancer Centers Bloomington, Bloomington
IU Health Central Indiana Cancer Centers, Indianapolis
IU Health Goshen Center for Cancer Care, Goshen
Jasper Memorial Hospital, Jasper
Kosciusko Community Hospital Cancer Care Center, Warsaw
Northern Indiana Cancer Research Consortium, South Bend
Ontology Hematology Associates of Southwest Indiana, Newburgh
Radiation Oncology Associates, Fort Wayne
St.Vincent Health, Indianapolis
Union Hospital, Inc., Terre Haute

IOWA
Siouxland Hematology Oncology Associates, LLP, Sioux City

KANSAS
Cancer Center of Kansas, Wichita

MARYLAND
Meritus Center for Clinical Research / John R. Marsh Cancer Center, Hagerstown

MICHIGAN
The Cancer Center at Metro Health Village, Wyoming
St. Joseph Mercy Hospital, Ann Arbor

MONTANA
Bozeman Deaconess Cancer Center (SCCA), Bozeman

NEBRASKA
Nebraska Methodist Hospital, Omaha

NEVADA
Comprehensive Cancer Centers of Nevada (TRIO), Henderson

NEW JERSEY
Fox Chase Hunterdon Regional Cancer Center, Flemington
South Jersey Healthcare, The Minniti Center (Fox Chase), Vineland
Regional Cancer Care Associates, LLC, Cherry Hill
Virtua Fox Chase Cancer Program, Mt. Holly

NEW MEXICO
Hematology Oncology Associates, Albuquerque
Memorial Medical Cancer Center, Las Cruces
Presbyterian Medical Group, Albuquerque

NORTH CAROLINA
Hope Women's Cancer Center (TRIO), Asheville

OKLAHOMA
Mercy Clinic Oncology and Hematology - McAuley, Oklahoma City

OREGON
Providence Cancer Center, Portland

PENNSYLVANIA
Allegheny General Hospital, Pittsburgh
Geisinger Medical Center, Danville
Gettysburg Cancer Center, Gettysburg
Grand View Hospital (Fox Chase), Sellersville
Magee-Womens Hospital of UPMC, Pittsburgh
Pennsylvania Oncology Hematology Associates (Fox Chase), Philadelphia
PinnacleHealth Cancer Care, Harrisburg
Reading Hospital Regional Cancer Center (Fox Chase), West Reading

SOUTH CAROLINA
Spartanburg Regional Healthcare System (MUSC), Spartanburg

TENNESSEE
The Jones Clinic PC, Germantown
The West Clinic, Memphis

TEXAS
Joe Arrington Cancer Research and Treatment Center, Lubbock
Medicus Alliance Clinical Research, Houston
Texas Oncology PA, Dallas

VIRGINIA
Virginia Oncology Associates, Norfolk

WASHINGTON
Group Health (SCCA), Seattle
Seattle Cancer Care Alliance at Evergreen Health (SCCA), Kirkland

WISCONSIN
Aurora Research Institute, LLC, Milwaukee

AUSTRALIA
Alfred Hospital, Melbourne
Ashford Cancer Centre, Adelaide
Austin Hospital, Melbourne
Gallipoli Medical Research Foundation, Brisbane
Launceston General Hospital, Launceston
Peninsula Oncology Centre, Frankston
Prince of Wales Hospital, Sydney
Princess Alexandra Hospital, Brisbane
Royal Adelaide Hospital, Adelaide
Royal Brisbane & Women's Hospital, Brisbane
Royal Perth Hospital, Perth
Royal Prince Alfred Hospital, Sydney
Sydney Adventist Hospital LTD, Sydney

CANADA
Cross Cancer Institute, Edmonton
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Tom Baker Cancer Centre, Calgary
Vancouver Centre – BC Cancer Agency, British Columbia

SINGAPORE
National Cancer Centre Singapore, Department of Medical Oncology
Recognizing Excellence in Research

Terry Hoeppner Patient Advocacy Award

Terry Hoeppner, beloved Indiana University football coach, lost his battle with brain cancer in 2007. Coach Hep was known for his “never quit” attitude and determination to face challenges head-on. To honor his memory, his wife, Jane Hoeppner, created the Terry Hoeppner Patient Advocacy Award. The award honors individuals who embody Coach Hep’s spirit and determination to champion their cause.

2013 Award Winner
Donald C. “Danny” Danielson

Sandra Turner Excellence in Clinical Research Award

The Sandra Turner Excellence in Clinical Research Award was established in 2002 by William B. Fisher, MD, through the George and Sarah Jane Fisher Fund to honor the memory of Sandra Turner, the first executive director of Hoosier Cancer Research Network. Recipients exemplify qualities which Sandra Turner possessed, such as sustained professional commitment, contribution to the progress of oncology care, and unflinching compassion.

2014 Award Winners
Deneise Francis, RN, BSN, OCN, CCRP
Gladys Pierce, RN, OCN
George and Sarah Jane Fisher Young Investigator Award

In 2011, William B. Fisher, MD, and others generously endowed a new award through the George and Sarah Jane Fisher Fund to challenge the next generation of cancer researchers. The George and Sarah Jane Fisher Young Investigator Award honors Indiana University oncology fellows and faculty members who have made significant contributions to clinical or basic science research in collaboration with Hoosier Cancer Research Network.

2014 Award Winners
Gregory Durm, MD
Daniela Matei, MD

Danny Danielson Translational Innovation Award

In 2013, Donald C. “Danny” Danielson established the Danny Danielson Translational Innovation Award, granted by the Walther Cancer Foundation. The award is given to investigators working in partnership with Hoosier Cancer Research Network to support the correlative components of clinical trial protocols when financial support is not otherwise available.

2014 Award Winners
Matthew Galsky, MD
E. Gabriela Chiorean, MD
Partnerships in Research

Indiana Department of the Ladies Auxiliary to the Veterans of Foreign Wars

For more than 100 years, the Ladies Auxiliary to the Veterans of Foreign Wars has served American veterans and active duty service members through a variety of programs, including Cancer Aid and Research. Each of its 4,500 member auxiliaries participates in raising funds toward the program. With more than 450,000 Ladies Auxiliary members nationwide, the impact is significant. Each year, state departments receive back a portion of their contribution to the Cancer Aid and Research program, and donate the funds to a research facility. In 2014, the Indiana Department raised $89,000 for cancer research, and received back nearly $12,500, which the organization donated to Hoosier Cancer Research Network.

Columbus North High School
Courage to Climb

When Columbus North High School choir director Janie Gordon was diagnosed with breast cancer in 2009, her students wanted to do something to encourage her. They secretly planned a benefit concert in her honor, naming it Courage to Climb, and donated proceeds to breast cancer research. As Courage to Climb became an annual event, Gordon wanted to expand the focus to include funding for other cancers. Hoosier Cancer Research Network was a good fit, with its long record of conducting clinical research in a variety of cancer types. Since 2011, Columbus North High School has donated more than $15,000 to HCRN through Courage to Climb.
Our Contributors

Hoosier Cancer Research Network thanks all those who have contributed to our organization. Our mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech partners with the goal of advancing cancer research, education, and patient advocacy. We are fortunate to have friends and supporters who give of their time and resources to help us fulfill our mission.

CONTRIBUTIONS RECEIVED JANUARY 1 - JUNE 30, 2014
(Contributions from the following are represented in the audited financial statements in this report)

Charles Margolis
William Fisher

CONTRIBUTIONS RECEIVED JULY 1 - DECEMBER 31, 2014
(Contributions from the following are not represented in the audited financial statements in this report)

Columbus North High School
  in honor of Janie Gordon
Christopher Fausel
  in memory of Stephen D. Williams, MD
Christopher Hoimes
  in memory of Mario Jackson
LeaEtta Hyer
  in memory of Lee and Wanetta Horath
Jennifer Klem
  in memory of Doug Hare
John Nell
Linda Nielsen
  in honor of Wilson E. Holycross
Tom Sibert
Indiana Department of the Ladies Auxiliary to the Veterans of Foreign Wars